AOP Orphan Pharmaceuticals Aktiengesellschaft
AOP Orphan Pharmaceuticals Aktiengesellschaft
Contact:
AOP
Phone: +43 503 72 44-24
E-Mail: olena.weissenbacher@aoporphan.com
KEYWORDS:
  • PV
  • Polycythemia Vera
  • Ropeginterferon alfa-2b
  • PharmaEssentia
  • AOP Orphan
Download Photos
AOP Orphan Pharmaceuticals Aktiengesellschaft (4 releases)

AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
3 abstracts were presented at the 22nd Congress of the European Hematology Association in Madrid
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid.

AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in PV
2017-06-25, pts20170625010 Products/Innovations, Health/Medicine
AOP Orphan starts EMA marketing authorization application procedure for Ropeginterferon alfa-2b
2017-03-14, pts20170314029 Health/Medicine, Products/Innovations